MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Sialorrhea"

  • 2022 International Congress

    IncobotulinumtoxinA for treating chronic sialorrhea due to Parkinson’s disease and other neurological conditions

    W. Jost, F. Pagan (Wolfach, Germany)

    Objective: To summarize clinical experience with incobotulinumtoxinA (INCO) for treating chronic sialorrhea due to Parkinson’s disease (PD), atypical parkinsonism, stroke, or traumatic brain injury in…
  • 2022 International Congress

    Evaluation of an Oral Health Questionnaire in Parkinson’s Disease to Facilitate a Multi-disciplinary Approach to improving Care Through Education

    J. Price, H. Martin, L. Ebenezer (Bronllys, Powys, United Kingdom)

    Objective: To determine if the oral health questionnaire (OHQ) devised could help to promote good oral hygiene in Parkinson’s disease (PD) while considering the potential…
  • 2022 International Congress

    IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: a real-life study

    B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, H. Couckuyt, M. van Zandijcke (Bruges & Ghent, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles (IC) into…
  • 2022 International Congress

    Comparison of Voice, Speech, Swallowing and Drooling Problems in Parkinson’s Disease Patients with Healthy Individuals

    M. Sapmaz Atalar, G. Genç, ş. Oğur (Istanbul, Turkey)

    Objective: To compare voice, speech, swallowing and drooling problems in Parkinson's disease (PD) patients with healthy individuals (HI) by using objective and subjective methods and…
  • MDS Virtual Congress 2021

    Efficacy of Incobotulinumtoxin/A Treatment for Children/Adolescents with Sialorrhea associated with Neurological Disorders

    S. Berweck, H. Kim, M. Banach, A. Hanschmann, M. Althaus, M. Bonikowski (Vogtareuth, Germany)

    Objective: The SIPEXI (Sialorrhea Pediatric Xeomin Investigation) study investigated efficacy and safety of intraglandular incobotulinumtoxinA (incoBoNT/A) injections in children/adolescents with sialorrhea associated with neurological disorders…
  • MDS Virtual Congress 2020

    Prevalence, impact, and factors associated with excessive buccal saliva in the COPARK database

    S. Perez-Lloret, L. Negre-Pages, P. Damier, A. Delval, P. Derkinderen, A. Destée, M. Fabbri, W. Meissner, A. Rachdi, F. Tison, O. Rascol (Buenos Aires, Argentina)

    Objective: To describe the prevalence of sialorrhea and drooling in Parkinson’s Disease (PD) patients of the COPARK study, to find factors associated to these conditions,…
  • MDS Virtual Congress 2020

    IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: A real-life study

    B. Bergmans, V. Schotte, N. Sys, E. Van Massenhove, M. Van Zandijcke (Brugge, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea (10 injection cycles into the…
  • 2019 International Congress

    Incidence of drooling in Parkinson’s Disease and Impact on Quality of Life

    B. Gibbons, B. Mohamed, C. Thomas (Cardiff, United Kingdom)

    Objective: The project aimed to determine the frequency and severity of drooling in the Parkinson’s Disease (PD) population in Cardiff & the Vale Health-board through…
  • 2019 International Congress

    Glycopyrrolate as inhalation for treating sialorrhea in Parkinson’s Disease

    L. Velzen, J. Masselink, L. Dorresteijn, K. Movig (Enschede, Netherlands)

    Objective: To evaluate the safety, tolerability and effect of glycopyrrolate inhalations in PD patients with sialorrhea. Background: Sialorrhea is reported in up to 60 percent…
  • 2019 International Congress

    Onset of action for rimabotulinumtoxinB in the treatment of adult sialorrhea

    L. Bahroo, S. Isaacson, R. Pahwa, D. Chary, T. Clinch, M. Lew (Washington, DC, USA)

    Objective: To assess the onset of action for rimabotulinumtoxinBinjections in the salivary glands for the treatment of sialorrhea. Background: Sialorrhea (drooling) causes significant morbidity including impaired oral…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley